Literature DB >> 1923364

The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate.

B E Klein1, S E Moss, R Klein, T S Surawicz.   

Abstract

Serum total and high-density lipoprotein (HDL) cholesterol were measured in a sample of individuals examined between 1984 and 1986 for the Wisconsin Epidemiologic Study of Diabetic Retinopathy. There was a significant trend for increasing severity of diabetic retinopathy and of retinal hard exudate with increasing cholesterol in insulin-using persons. Cholesterol levels were not related to the severity of either ocular condition in older-onset patients. High-density lipoprotein-cholesterol was unrelated to the severity of either lesion. In multiple logistic regression analyses, cholesterol was not a significant factor in describing the severity of retinopathy in any group but was a significant factor in describing the severity of retinal hard exudate. Glycosylated hemoglobin and diastolic blood pressure were significant descriptors of the severity of retinopathy in younger-onset patients in these multivariate analyses. Diastolic blood pressure added significantly to explaining the severity of hard exudate in older-onset insulin users. These data support the current management strategies for diabetes, which include control of level of glycemia, blood pressure, and blood lipids.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1923364     DOI: 10.1016/s0161-6420(91)32145-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  66 in total

1.  Atherosclerotic cardiovascular disease and diabetic retinopathy.

Authors:  Jorge G Arroyo
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

2.  Statins for prevention of diabetic-related blindness: a new treatment option?

Authors:  Mona F El-Azab; Barbara A Mysona; Azza B El-Remessy
Journal:  Expert Rev Ophthalmol       Date:  2011-06

3.  Diabetic retinopathy: should this patient receive laser treatment? Overview.

Authors:  E Chew
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

4.  The relation of atherosclerotic cardiovascular disease to retinopathy in people with diabetes in the Cardiovascular Health Study.

Authors:  Ronald Klein; Emily K Marino; Lewis H Kuller; Joseph F Polak; Russell P Tracy; John S Gottdiener; Gregory L Burke; Larry D Hubbard; Robin Boineau
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

5.  Association of serum lipid levels with retinal hard exudate area in African Americans with type 2 diabetes.

Authors:  Evangelia Papavasileiou; Samaneh Davoudi; Ramak Roohipoor; Heeyoon Cho; Shreyas Kudrimoti; Heather Hancock; James G Wilson; Christopher Andreoli; Deeba Husain; Maurice James; Alan Penman; Ching J Chen; Lucia Sobrin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-15       Impact factor: 3.117

6.  Clinical and metabolic factors associated with the blood retinal barrier permeability in insulin dependent diabetes mellitus without retinopathy.

Authors:  J M Benitez del Castillo; A Castillo; P C Fernandez; J Garcia Sanchez
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

Review 7.  'Statins in retinal disease'.

Authors:  Ahmed Al-Janabi; Sue Lightman; Oren Tomkins-Netzer
Journal:  Eye (Lond)       Date:  2018-03-20       Impact factor: 3.775

8.  Hyperlipidemia and the development of diabetic retinopathy: Comparison between type 1 and type 2 animal models.

Authors:  Renu A Kowluru; Manish Mishra; Anjaneyulu Kowluru; Binit Kumar
Journal:  Metabolism       Date:  2016-07-30       Impact factor: 8.694

9.  Current and future approaches in the prevention and treatment of diabetic retinopathy.

Authors:  Louis K Chang; David Sarraf
Journal:  Clin Ophthalmol       Date:  2008-06

10.  Pharmacologic therapies for diabetic retinopathy and diabetic macular edema.

Authors:  Ehud Rechtman; Alon Harris; Hanna J Garzozi; Thomas A Ciulla
Journal:  Clin Ophthalmol       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.